K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · AMGN
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-22 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $10K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2026-04-20 | AMGN | AMGEN INC | AMGEN, INC. | $2.6M | Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Ac |
| 2026-04-20 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2026-04-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2026-04-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2026-04-20 | AMGN | AMGEN INC | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs federal budget issues |
| 2026-04-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2026-04-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. 340B. |
| 2026-04-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues. |
| 2026-04-17 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research |
| 2026-04-17 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability. Issues related to the 340B Program - Public Health Service Act (PL 78-410). |
| 2026-04-17 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2026-04-13 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2026-04-10 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $0 | |
| 2026-04-09 | AMGN | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. | B HALL STRATEGIES, LLC | $50K | Issues related to drug pricing. |
| 2026-03-12 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2026-03-09 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2026-01-26 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2026-01-20 | AMGN | AMGEN INC | AMGEN, INC. | $3.5M | Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to drug pricing Issues related to cardiov |
| 2026-01-20 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2026-01-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2026-01-20 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability. Issues related to the 340B Program - Public Health Service Act (P.L. 78-410). |
| 2026-01-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2026-01-20 | AMGN | AMGEN INC | TARPLIN, DOWNS & YOUNG, LLC | $60K | Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs federal budget issues IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency |
| 2026-01-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2026-01-20 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2026-01-19 | AMGN | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. | B HALL STRATEGIES, LLC | $50K | Issues related to drug pricing. |
| 2026-01-19 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. |
| 2026-01-19 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $20K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2026-01-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2026-01-16 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research |
| 2026-01-16 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2026-01-12 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2025-11-12 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2025-10-20 | AMGN | AMGEN INC | AMGEN, INC. | $3.5M | Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red |
| 2025-10-20 | AMGN | AMGEN INC | AMGEN, INC. | $2.6M | Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H |
| 2025-10-20 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research |
| 2025-10-20 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-10-20 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act". Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. |
| 2025-10-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-10-20 | AMGN | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. | B HALL STRATEGIES, LLC | $50K | Issues related to drug pricing. Monitor Public Law 119-21: One Big Beautiful Bill Act. |
| 2025-10-20 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-10-19 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability. Issues related to the 340B Program - Public Health Service Act (P.L. 78-410). |
| 2025-10-19 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform. |
| 2025-10-19 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-10-17 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2025-10-15 | AMGN | AMGEN INC | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs federal budget issues |
| 2025-10-14 | AMGN | AMGEN INC. | HILLNORTH LLC | $38K | Issues related to the pharmaceutical industry. |
| 2025-10-14 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $15K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-10-11 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-09-25 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-07-21 | AMGN | AMGEN INC | AMGEN, INC. | $2.6M | Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H |
| 2025-07-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars |
| 2025-07-21 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-07-21 | AMGN | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. | B HALL STRATEGIES, LLC | $50K | Issues related to drug pricing in the One Big Beautiful Bill Act (PL 119-21). |
| 2025-07-21 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. |
| 2025-07-21 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $15K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-07-20 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs. |
| 2025-07-19 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-07-19 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to Medicare Part D drug rebates. |
| 2025-07-19 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | |
| 2025-07-18 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research |
| 2025-07-18 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | Issues related to patent protections. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act". Tax issues related to the pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act". Policies impacting disease prevention. Issues related to antitrust legislation. |
| 2025-07-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform. |
| 2025-07-17 | AMGN | AMGEN INC. | HILLNORTH LLC | $35K | Issues related to the pharmaceutical industry. |
| 2025-07-16 | AMGN | AMGEN INC | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, 340B, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, 340B federal budget issues |
| 2025-07-15 | AMGN | TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. | B HALL STRATEGIES, LLC | $0 | Issues related to drug pricing and reimbursement for prescription drugs. |
| 2025-07-14 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $8K | issues related to pharmaceutical drugs |
| 2025-04-21 | AMGN | AMGEN INC | AMGEN, INC. | $3.6M | Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE) Issues related to direct-to-consumer advertising Issues related to obesity disease awareness and treatment Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to |
| 2025-04-21 | AMGN | AMGEN INC. | TODD STRATEGY GROUP | $80K | Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy. |
| 2025-04-21 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals. Tax issues related to the pharmaceutical industry. Policies impacting disease prevention. Issues related to antitrust legislation Issues related to patent protections. |
| 2025-04-21 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019 Issues related to health care research in FY26 Labor Health and Human Services Subcommittee |
| 2025-04-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-04-21 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-04-21 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid rebate and best price. |
| 2025-04-20 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $10K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-04-18 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement for prescription drugs provision in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D drug rebates. |
| 2025-04-18 | AMGN | AMGEN INC. | CAPITOL COUNSEL LLC | $50K | Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. |
| 2025-04-18 | AMGN | AMGEN INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to PBM reform; 340B and biosimilars. |
| 2025-04-17 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-04-15 | AMGN | AMGEN INC | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, 340B, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, 340B federal budget issues |
| 2025-04-15 | AMGN | AMGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $8K | issues related to pharmaceutical drugs |
| 2025-04-11 | AMGN | AMGEN INC. | HILLNORTH LLC | $30K | Issues related to the pharmaceutical industry. |
| 2025-02-04 | AMGN | AMGEN INC | AMGEN, INC. | $3.0M | Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 1613 to amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program HR 4818/ S. 2407 Treat and Reduce Obesity Act S. 2305 Biosimilar Red Tape Elimination Act S. 2129 Ensuring Access to Lower-Cost Medicines for Senior |
| 2025-01-31 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $0 | Educating members on issues impacting Amgen and patients |
| 2025-01-22 | AMGN | AMGEN INC. | WILLIAMS AND JENSEN, PLLC | $60K | General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Tax issues related to the pharmaceutical industry. Policies impacting disease prevention. Issues related to antitrust legislation Issues related to patent protections. |
| 2025-01-22 | AMGN | AMGEN INC. | FEDERAL HEALTH COUNSEL, LLC | $0 | Issues relating to the implementation of Medicare Drug Negotiations and the calculation of Medicaid best price. |
| 2025-01-21 | AMGN | AMGEN INC | AMGEN, INC. | $2.8M | Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 5378 Lower Costs, More Transparency Act R 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act HR 3503 The NIH Clinical Trials Diversity Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers Proposed r |
| 2025-01-21 | AMGN | AMGEN INC. | RICCHETTI INCORPORATED | $60K | Issues related to drug pricing and access, Medicare and Medicaid reimbursement; Issues relating to the Medicaid drug rebate program proposed rule Issues related to pharmaceutical industry, generally; Drug pricing and access, and Medicare and Medicaid reimbursement |
| 2025-01-21 | AMGN | AMGEN INC. | MILLER STRATEGIES, LLC | $60K | Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas |
| 2025-01-20 | AMGN | AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. | S-3 GROUP | $60K | H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe Step Act |
| 2025-01-20 | AMGN | AMGEN INC. | TIBER CREEK HEALTH STRATEGIES, INC. | $50K | Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169). |
| 2025-01-20 | AMGN | AMGEN INC. | BGR GOVERNMENT AFFAIRS | $50K | Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform. |
| 2025-01-20 | AMGN | AMGEN INC. | WASHINGTON ADVOCACY GROUP | $20K | Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests |
| 2025-01-19 | AMGN | AMGEN INC | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement for prescription drugs provision in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D drug rebates. |